PFE Fair Price
$41.26
Fair Price Index
The fair price of a share represents the true value of the company's share based on its financial condition and performance. Unlike the current market price, which can fluctuate depending on the mood of the market, the fair price provides us with a better understanding of whether the share is truly advantageous.
Overvalued by 9.8%
To display the fair price of a share, you need to be a member of Bulios Black.
My Notes
Začít psátFeed
Read More
🗓️Přehled of this week's events you shouldn't miss!
Hey investors here's another round-up of highlights for the week ahead. In my opinion, this week will be one of the most interesting earnings weeks.
Monday: Earnings: Before the markets open ONSemi $ON, a semiconductor company that currently has a major partnership with Volkswagen, will report earnings . We'll alsoget results...
Read more
Read More
💵 Three reliable dividend stocks with a yield above 5%!
Here is my pick of 3 interesting dividend companies from different sectors.
These companies are known for their long history of raising dividends every year and at current prices offer yields over 5 %. Although dividend increases are not expected to be huge somehow, their stability and advantages over their competitors make...
Read more
Zobrazit další komentáře
Super post👍. I have all 3 in my portfolio, but I plan to sell PFE when I see it in the green.
Read More
What is your current perception of the $PFE?
For me, a fine company that pays a nice dividend, but I don't have this company in my portfolio because of the dividend. For me, Pfizer is a bit of a speculation, so when the stock in my portfolio starts to turn at least a little green, I'll start selling.
Zobrazit další komentáře
PFE is a company that has not outperformed the index for me, when I look back 10 years it has virtually zero growth in all possible metrics except the pandemic. These exceptional profits have been distributed in bonuses, they have bought back some shares at bad prices and the rest has been wasted on acquisitions that are necessary to replace expiring patents and the outcome is very uncertain.
A shareholder who didn't sell at the top has zero profit in 10y, not counting dividends. These have increased over the last 5 years by about 5% and 3 years (covid!) 3%, so you can get an impression of how they think of (divi) shareholders.
I sold PFE in 2022 and very much regret buying it back last year, hold experience;)
Zobrazit další komentáře
$VLD I tried to catch the falling knife but it was halfway there so it didn't help much. See:
https://bulios.com/status/139039
Well it was enlightening as to how a potential rocket can be grafted. I'm holding because it's already a negligible amount and maybe it will still vyhrabe🤷♂️
Read More
📊 Investment Calendar 📆
Earnings season is in full swing, and with it comes more exciting news. Here is a summary of the news I will be following.
Monday: I'll only be watching company results.
📈 Earnings: Before the markets open, I'll be watching Domino's Pizza $DPZ, SoFi Technologies $SOFI and ON Semiconductor $ON. After the close, just the results of Paramount $PARA and Logit...
Read more
Zobrazit další komentáře
Yes, I always buy under $100 at the beginning of the year and the plan is to keep buying until the end of the year. Only if it goes on like this I will have to rethink the maximum purchase 😉 As I have written several times mRNA technology is one of the most important discoveries.
10M
Read More
Investors, what is your current perception of Pfizer ?
I am currently -18%on $PFEstock . My view doesn't change based on whether I'm + or -, but unfortunately I don't see as much potential here and I don't see any stability/certainty. If I get to + in this position, I will sell as soon as possible and put the money elsewhere.
Zobrazit další komentáře
I didn't like the outlook at all, so I evaluated moving my money elsewhere... It came in handy, too, as I wanted to whittle my portfolio down to 10-12 titles. I'm glad I don't have to deal with Pfizer anymore.
Read More
📈💡 New and interesting player on the pharmaceutical market! 💊🔍
One of the most discussed topics in the pharmaceutical market is the treatment of obesity and diabetes. Only two companies are behind many successful drugs such asOzempic, Rybelsus and Saxenda: Novo Nordisk $NVO and Eli Lilly $LLY. These companies have had significant success in the treatment of diabetes and...
Read more
11M
Zobrazit další komentáře
I don't, but at that price I'm thinking pretty strongly about a smaller position.
Zobrazit další komentáře
So we'll see how it turns out, as Marek writes, not every acquisition has to be so profitable. However, I have PFE shares in my portfolio and I am waiting for the growth.
Thanks for the overview. There's a lot of results out there and it's going to be a busy week overall. I'm currently on vacation, but I'll at least try to follow it a bit😁